- Trials with a EudraCT protocol (44)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44 result(s) found for: Elevated liver enzymes.
Displaying page 1 of 3.
EudraCT Number: 2005-003231-46 | Sponsor Protocol Number: 0001 | Start Date*: 2005-11-04 |
Sponsor Name:Dept of Internal Medicine IV, Med Uni Vienna | ||
Full Title: Changes in hepatic lipid content assessed by MR Spectroscopy in patients with non-alcoholic fatty liver disease (NAFLD) under standard therapy (reduction diet and regular aerobic exercise) with and... | ||
Medical condition: Nonalcoholic fatty liver disease (NAFLD) is a potentially progressive liver disease, leading to cirrhosis in up to 26% of affected patients and rarely hepatocellular carcinoma. Several studies have... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-017148-15 | Sponsor Protocol Number: CCOX189A2483 | Start Date*: 2010-04-12 |
Sponsor Name:NOVARTIS FARMA | ||
Full Title: A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126,... | ||
Medical condition: patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004645-36 | Sponsor Protocol Number: TMP-2501-2019-2 | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:Fraunhofer Gesellschaft for its Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) | |||||||||||||
Full Title: Impact of different silymarin dosages to decrease drug-induced elevated liver enzymes compared to placebo in a prospective controlled dose finding Phase IIb trial (SILVER) | |||||||||||||
Medical condition: Drug-induced elevated liver enzymes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012916-41 | Sponsor Protocol Number: CICL670EDE08T | Start Date*: 2010-01-12 | |||||||||||
Sponsor Name:CROLLL GmbH | |||||||||||||
Full Title: The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a prospective open-label phase I/II trial | |||||||||||||
Medical condition: To assess the clinical and biological activity of Deferasirox in patients with NASH and increased iron storage / disturbed distribution of iron on liver function and liver histology | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004212-21 | Sponsor Protocol Number: AMAG-423-201 | Start Date*: 2019-05-24 | |||||||||||
Sponsor Name:AMAG Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Pree... | |||||||||||||
Medical condition: Severe Preeclampsia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001501-41 | Sponsor Protocol Number: 156-13-208 | Start Date*: 2016-01-16 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | ||
Full Title: A Multinational Trial to Collect Blood Samples to Explore Potential Genetic/Biomarkers Related to Increased Risk of Liver Injury in Adult Subjects from Prior Tolvaptan Clinical Trials for Autosomal... | ||
Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD), Patients with Increased Risk of Liver Injury | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-003816-47 | Sponsor Protocol Number: Met-ADI-01 | Start Date*: Information not available in EudraCT |
Sponsor Name:Pädiatrische Endokrinologie, Universitätsmedizin Berlin, Charité | ||
Full Title: Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance Klinische Pilotstudie zur Untersuchung der Wirkung von Metformin bei adipösen Kindern un... | ||
Medical condition: Insuline-resistance in adipose children and adolescents | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000413-31 | Sponsor Protocol Number: 15871A | Start Date*: 2014-07-24 | ||||||||||||||||
Sponsor Name:H. Lundbeck A/S | ||||||||||||||||||
Full Title: Exploratory, interventional, open-label, fixed-dose study with Selincro® as-needed use, in alcohol dependent patients with liver impairment | ||||||||||||||||||
Medical condition: Alcohol dependence and liver impairment related to alcohol consumption | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002408-15 | Sponsor Protocol Number: Ipi4 | Start Date*: 2013-11-05 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Phase IV ipilimumab in melanoma A National, Multicenter, Interventional Study in Patients with Unresectable or Metastatic Melanoma | ||
Medical condition: Patients diagnosed with unresectable or metastatic melanoma, cutaneous, ocular, mucosal and unknown primary tumor | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002947-27 | Sponsor Protocol Number: SIMCODE | Start Date*: 2020-01-22 |
Sponsor Name:Charité – Universitätsmedizin Berlin | ||
Full Title: Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial | ||
Medical condition: Patients with comorbid obesity (body mass index ≥ 30) and major depression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002007-13 | Sponsor Protocol Number: CXUO320BDE35 | Start Date*: 2006-06-29 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A randomized, active-controlled, open-label, multicenter cross-over study with two 6-week treatment periods to investigate the effect of the combination of Lescol XL (fluvastatin) 80 mg and fenofib... | |||||||||||||
Medical condition: Dyslipidaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010951-28 | Sponsor Protocol Number: CLTR0308-205 | Start Date*: 2009-09-30 | |||||||||||
Sponsor Name:Celator Pharmaceuticals, Inc | |||||||||||||
Full Title: Phase IIB, multicenter, randomized, open-label trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adult patients ≤ 60 years old with AML in first rela... | |||||||||||||
Medical condition: Acute myeloid leukemia recurrent (Acute Myeloid Leukemia in First Relapse Following an Initial CR >1 Month Duration). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000482-36 | Sponsor Protocol Number: LUM001-201 | Start Date*: 2013-07-08 | |||||||||||
Sponsor Name:Lumena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTi), IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA)... | |||||||||||||
Medical condition: Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005385-38 | Sponsor Protocol Number: GFT505-315-1 | Start Date*: 2016-03-04 | ||||||||||||||||
Sponsor Name:Genfit SA | ||||||||||||||||||
Full Title: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (NASH) and fibrosis. | ||||||||||||||||||
Medical condition: Non-Alcoholic Steatohepatitis (NASH) and fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) GB (Completed) DE (Completed) CZ (Prematurely Ended) SE (Completed) IT (Prematurely Ended) PT (Completed) NL (Completed) DK (Prematurely Ended) FI (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-005876-21 | Sponsor Protocol Number: DANOHCA-001 | Start Date*: 2022-07-08 | |||||||||||
Sponsor Name:Department of Cardiology, Copenhagen University Hospital, Rigshospitalet | |||||||||||||
Full Title: The Danish Out-of-Hospital Cardiac Arrest study (DANOHCA) | |||||||||||||
Medical condition: We will investigate the efficacy of four interventions (two pharmaceutical) for reducing mortality and organ damage in patients resuscitated after out-of-hospital cardiac arrest. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002936-26 | Sponsor Protocol Number: 17-157 | Start Date*: 2019-11-28 |
Sponsor Name:Heinrich-Heine-University Düsseldorf | ||
Full Title: Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with Cholangiocarcinoma | ||
Medical condition: Patients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002557-23 | Sponsor Protocol Number: ATH001-CLN01 | Start Date*: 2007-11-02 | |||||||||||
Sponsor Name:Advancell Advanced In Vitro Cell Technologies, S.A | |||||||||||||
Full Title: A Phase I/II Open-Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients with B-Cell Chronic Lymphocytic Leukaemia | |||||||||||||
Medical condition: Patients with B-Cell Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003709-33 | Sponsor Protocol Number: AIO-HEP-0116 | Start Date*: 2017-05-04 | |||||||||||||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||||||||||||
Full Title: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies | |||||||||||||||||||||||||||||||||
Medical condition: advanced, unresectable and metastatic cholangio- and gallbladder carcinoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003320-40 | Sponsor Protocol Number: EP-003 | Start Date*: 2023-03-14 | |||||||||||
Sponsor Name:Empros Pharma AB | |||||||||||||
Full Title: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001069-28 | Sponsor Protocol Number: D5881C00004 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH) | |||||||||||||
Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
